Agreement - June 7, 2016
AZ licenses Zurampic to Grünenthal GmbH
AstraZeneca has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. Zurampic was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the adjunctive treatment of hyperuricemia (excess of uric acid in the blood) […]
Pharma Business - May 31, 2016
Positive CHMP opinion in EU for saxa/dapa
AstraZeneca announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. The fixed-dose combination of saxagliptin and dapagliflozin has the potential to be the first DPP-4i/SGLT-2i combination […]
Collaboration - May 31, 2016
Antaros in collaboration with Sahlgrenska and AstraZeneca
Antaros Medical, Sahlgrenska University Hospital and AstraZeneca have announced a kidney imaging collaboration aiming to develop new tools to treat chronic kidney disease (CKD). The collaboration partners will work together on a study to examine a range of imaging endpoints in patients with CKD. The aim is to determine which imaging biomarkers are best suited to follow CKD progression […]
Clinical Trials - May 30, 2016
AZ’s Faslodex met primary endpoint
AstraZeneca announces positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) toArimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer. Faslodex 500mg demonstrated superiority compared with Arimidex 1mg in FALCON, and met its primary […]
Clinical Trials - May 23, 2016
AZ provides positive results from Lynparza trial
AstraZeneca has announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein. Whilst there […]
Clinical Trials - May 19, 2016
AZ announces positive results from phase III programme
Benralizumab, AZ’s potential new medicine and anti-eosinophil monoclonal antibody, has been well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials. This demonstrates significant reductions in the annual asthma exacerbation rate compared to placebo. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “Severe asthma affects the health […]
